<DOC>
	<DOC>NCT00138632</DOC>
	<brief_summary>This study evaluates the tolerability and safety of 3 months treatment with PTK787 tablets given daily. It also explores the efficacy of the compound in patients with wet age-related macular edema. In Cohort 1 verteporfin/PDT is the active control. The protocol was amended to reflect the current standard of care for AMD. As a result, ranibizumab is the active control for Cohort 2.</brief_summary>
	<brief_title>Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Inclusion criteria Male ≥ 65 years old or female ≥ 50 years old, with aged related macular degeneration Patients with subfoveal choroidal neovascularization secondary to AMD Exclusion criteria Eye disease that may result in visual loss during the study Uncontrolled high blood pressure, despite chronic stable treatment: systolic ≥ 140 mmHg, Diastolic ≥ 90 mmHg Chronic therapy with topical, local or systemic corticosteroids. Use of other investigational drugs within 30 days Pregnant or nursing (lactating) women. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Wet Age-related macular degeneration</keyword>
	<keyword>PTK787</keyword>
</DOC>